Detalhe da pesquisa
1.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
2.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
3.
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Blood
; 141(24): 2932-2943, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862975
4.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood
; 139(12): 1794-1806, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699592
5.
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality.
Transfusion
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693089
6.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
7.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
8.
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Br J Haematol
; 199(3): 366-370, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892294
9.
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis.
Blood
; 136(26): 3051-3055, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961550
10.
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Lancet Oncol
; 22(10): 1391-1402, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534514
11.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888407
12.
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Blood
; 134(7): 606-613, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186274
13.
Ultrasound Doppler and tenosynovial fluid analysis in tenosynovitis.
Ann Rheum Dis
; 79(7): 908-913, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213497
14.
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Blood
; 131(25): 2836-2845, 2018 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29549175
15.
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
Blood
; 129(13): 1791-1801, 2017 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126925
16.
Assessing Unwanted Variations in Rheumatology Clinic Previsit Rooming.
J Clin Rheumatol
; 25(3): e1-e7, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29757802
17.
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Blood
; 128(2): 195-203, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27247136
18.
Clonal myeloid disorders following CAR T-cell therapy.
Ann Hematol
; 102(12): 3643-3645, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37749320
19.
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Br J Haematol
; 176(6): 929-938, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28107546
20.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Blood
; 126(3): 354-62, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26048911